Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers.

Oncotarget - 1 Oct 2010

Herbert Brittney-Shea, Chanoux Rebecca A, Liu Yunlong, Baenziger Peter H, Goswami Chirayu P, McClintick Jeanette N, Edenberg Howard J, Pennington Robert E, Lipkin Steven M, Kopelovich Levy

Abstract excerpt

Specific changes in gene expression during cancer initiation should enable discovery of biomarkers for risk assessment, early detection and targets for chemoprevention. It has been previously demonstrated that altered mRNA and proteome signatures of morphologically normal cells bearing a single inherited "hit" in a tumor suppressor gene parallel many changes observed in the corresponding sporadic cancer. Here, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aza Compounds
Share to Bridged Bicyclo Compounds, Heterocyclic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Ductal, Breast

Share to Epithelial Cells

Share to Haploinsufficiency

Share to Li-Fraumeni Syndrome

Share to Pyrimidines

Share to Stromal Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 21311097
DOI: 10.18632/oncotarget.175
PMCID: PMC3039408

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers.PMID 21311097Read ↗

BRCA1 and BRCA2 germline mutations driven signaling pathway alterations are sufficient to initiate breast tumorigenesis by the PIK3CA <sup>H1047R</sup> oncogeneSemantic proximity Read ↗

Signaling Pathway Alterations Driven by BRCA1 and BRCA2 Germline Mutations are Sufficient to Initiate Breast Tumorigenesis by the PIK3CAH1047R OncogeneSemantic proximity Read ↗

Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort.Semantic proximity Read ↗

Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations.Semantic proximity Read ↗

Li–Fraumeni Syndrome: Mutation of TP53 Is a Biomarker of Hereditary Predisposition to Tumor: New Insights and Advances in the TreatmentSemantic proximity Read ↗

Inherited TP53 Mutations and the Li-Fraumeni Syndrome.Semantic proximity Read ↗

Drastic effect of germline TP53 missense mutations in Li-Fraumeni patients.Semantic proximity Read ↗

Transcriptional profiling reveals a subset of human breast tumors that retain wt <i>TP53</i> but display mutant p53-associated featuresSemantic proximity Read ↗

Multidimensional quantitative phenotypic and molecular analysis reveals neomorphic behaviors of p53 missense mutantsSemantic proximity Read ↗

New Paradigms in the Clinical Management of Li-Fraumeni Syndrome.Semantic proximity Read ↗

Signatures of post-zygotic structural genetic aberrations in the cells of histologically normal breast tissue that can predispose to sporadic breast cancer.Semantic proximity Read ↗

Li–Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.